← Back to Search

Study Medicine for Healthy Adults

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial tests a new drug called PF-07853578 on adults to see if they can handle it without major issues. Researchers will measure side effects and how much of the drug enters the bloodstream.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort 3Experimental Treatment2 Interventions
Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
Group II: Cohort 2Experimental Treatment2 Interventions
Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
Group III: Cohort 1Experimental Treatment2 Interventions
Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07853578
2023
Completed Phase 1
~30
Placebo
1995
Completed Phase 3
~2670

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,625 Previous Clinical Trials
14,284,171 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,518 Previous Clinical Trials
11,458,747 Total Patients Enrolled

Media Library

Cohort 3 Clinical Trial Eligibility Overview. Trial Name: NCT05890105 — Phase 1
Healthy Subjects Research Study Groups: Cohort 3, Cohort 1, Cohort 2
Healthy Subjects Clinical Trial 2023: Cohort 3 Highlights & Side Effects. Trial Name: NCT05890105 — Phase 1
Cohort 3 2023 Treatment Timeline for Medical Study. Trial Name: NCT05890105 — Phase 1
~10 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top